Effect of a single day of increased as-needed budesonide–formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study

This post-hoc analysis found PRN budesonide-formoterol reduced short-term risk of severe exacerbations after a single day of higher use (more than two inhalations; HR 0.27 [95% CI 0·12–0·58; p=0.0008] vs PRN terbutaline). These findings need confirmation in prospective RCTs.

Source:

The Lancet Respiratory Medicine